Centro de Atencion e Investigacion Medica
Quick facts
Marketed products
- Actilitio® · Oncology
Actilitio is a monoclonal antibody that targets the PD-1 receptor. - Eltrombopag (EPAG) · Hematology
Eltrombopag is a thrombopoietin (TPO) receptor agonist that stimulates platelet production by binding to and activating the TPO receptor on bone marrow megakaryocytes. - Revolade® · Hematology
Revolade (eltrombopag) is a thrombopoietin receptor agonist that stimulates platelet production by binding to and activating the TPO receptor on bone marrow progenitor cells. - Rivotril®
- Theralite®
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Centro de Atencion e Investigacion Medica portfolio CI brief
- Centro de Atencion e Investigacion Medica pipeline updates RSS
Frequently asked questions about Centro de Atencion e Investigacion Medica
What are Centro de Atencion e Investigacion Medica's marketed drugs?
Top marketed products include Actilitio®, Eltrombopag (EPAG), Revolade®, Rivotril®, Theralite®.
Related
- Actilitio® · Oncology
- Eltrombopag (EPAG) · Hematology
- Revolade® · Hematology
- Rivotril®
- Theralite®
- Sector hub: All tracked pharma companies